findmyKOL
Clinical trialNCT06333678CompletedPhase 2Interventional

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

SponsorMemorial Sloan Kettering Cancer CenterEnrollment10Non-Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The researchers will see whether this switch to sotorasib can control LANSCLC longer compared to the treatment approach of staying on durvalumab (and not switching to sotorasib).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Miami (data Collection Only)

    Miami, Florida, United States

  • University of Michigan (data Collection Only)

    Ann Arbor, Michigan, United States

  • Memorial Sloan Kettering Basking Ridge (all Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (all Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (all Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Suffolk - Commack (all Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (all Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (all Protocol Activities)

    Uniondale, New York, United States

  • Vanderbilt University (data Collection Only)

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DurvalumabSotorasib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Mar 2024
Primary completion
27 Jan 2026
Completion
27 Jan 2026
Last update posted
29 Jan 2026
Registered enrollment
10
Registry id
NCT06333678
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.